Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 | P30926 | 9/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 9/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.34 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31572160 | 1.00 | CHRNB4 (0.35) | CHRNB4CHRNA3CHRNB2CHRNA4LMNA | |
| SCHEMBL30832371 | 0.67 | GRM5 (0.40) | LMNAHTTSMN1; SMN2NCOA3HRH4 | |
| SCHEMBL21311774 | 0.67 | CHRNB4 (0.50) | CHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL30937441 | 0.66 | CHRNB4 (0.35) | CHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL29999565 | 0.66 | GRM5 (0.48) | LMNAHTTSMN1; SMN2HRH4 | |
| SCHEMBL31578578 | 0.64 | — | — | |
| SCHEMBL23416755 | 0.60 | CHRNB4 (0.31) | CHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL17827750 | 0.59 | PDGFRB (0.50) | LMNASMN1; SMN2HRH4 | |
| SCHEMBL22825538 | 0.58 | — | — | |
| SCHEMBL30789308 | 0.58 | PTK2 (0.40) | LMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025096738-A1 | KRAS INHIBITORS | INCYTE CORPORATION (US) | 2025-05-08 | — | — | WO | disclosed |